The impact on Britain’s bodies, baskets and businesses

Appetite for disruption: What GLP-1 means for consumer markets

Young woman in kitchen looking at laptop while cooking
  • June 2026

A single class of medication is changing how millions eat, drink, exercise and shop. GLP-1 has been around since the early 2000s but the approval of a pill for weight loss in June 2026 is a tipping point. The number of adults using GLP-1 today could increase by 2.5x from c.3m (5% adoption) to c.7m users (13% adoption) with the approval of a pill format for weight loss.

The impact on Britain’s bodies, baskets and businesses is only beginning to be understood. So, we have surveyed more than 2,300 adults in the UK to gain a deeper understanding of who is using GLP-1s and how their behaviour is changing across six categories: food, alcohol, supplements, apparel, restaurants and fitness. What we found has real consequences for any brand or retailer competing for a share of GLP-1 consumer spend.

2.5x

as many adults could take GLP-1s over the next year with the approval of a pill format for weight loss

80%

of past users maintain at least some of their dietary changes after stopping GLP-1s

83%

of potential users would be more likely to take GLP-1 in a pill format

Who your GLP-1 customers are, and how your category changes, will dictate how you compete

GLP-1 is reshaping the relationship consumers have with their bodies, what they choose to put in their basket and how businesses can best serve the end-to-end GLP-1 customer journey.

GLP-1 usage is set to move beyond the 9% of UK early adopters who are currently using it or have used it in the past, with an additional 18% of UK adults saying they would consider it. The profile of current users represents a mix of genders, ages and income, suggesting GLP-1s are going mainstream.

GLP-1 is not just changing our bodies, it is changing our shopping baskets and impacting how businesses serve consumers. GLP-1 is acting as both a spending catalyst and a spending multiplier, creating new consumer preferences and accelerating the adoption of others. Users are spending less in appetite-led categories such as indulgence within grocery, alcohol and eating out, and more in categories that support nutrition, fitness and confidence, many of these behaviours persist beyond treatment.

The wider GLP-1 ecosystem is now influencing the shape and profitability of the consumer economy. Who your GLP-1 customers are, and how your category changes, will dictate how you compete. Leading businesses will do three things at once: reshape their portfolios to manage near-term risk, innovate to capture changing preferences, and collaborate across the wider GLP-1 ecosystem to claim a bigger share of the profit.

Is the shift in your category temporary, or permanent? Most businesses don't yet know.
Download the full report

GLP-1: Changing Britain’s bodies, baskets and businesses

The impact of GLP-1 reaches far beyond treatment itself. It is reshaping who consumers are, how they spend, and how businesses will need to respond.

Bodies

Who is using GLP-1, why are they using it, and how is access changing across NHS, private and digital channels?

Current GLP-1 usage is concentrated among women and working-age adults, and uptake is democratising across income groups. But motivations and access shift markedly by generation and life stage.

Our full report profiles who the GLP-1 consumer really is, and why adoption may accelerate faster than expected.

Baskets

GLP-1 is not just changing our bodies, it is changing our shopping baskets. It is acting as both a spending catalyst and a spending multiplier and many of these behaviours persist beyond treatment.

For every category losing share of basket, another is gaining it, and many of these behaviours persist beyond treatment.

Our full report shows where spend is falling, where it is shifting, and which changes are temporary versus structural.

Businesses

How should businesses reshape, innovate and collaborate to manage the risks and capture the opportunities of GLP-1?

Some categories face structural exposure while others stand to gain, and the winners will act on all three fronts at once.

Our full report sets out how leaders can respond across portfolio, proposition and ecosystem.

“GLP-1 is the most consumerised medication today. People are shopping for GLP-1 as they would everyday items with a focus on brand, value, efficacy, convenience and trust.”

Jacqueline Windsor
Strategy& Partner and Head of Retail

GLP-1 Consumption changes

To understand the real impact, we mapped every category against two questions: how consumption changes during treatment, and what happens after it stops. That reveals four very different outcomes, from categories under sustained pressure, to those whose decline is only temporary, to those set for sustained growth.

One finding stands out. Over 80% of past users maintain at least some of their dietary changes after stopping. The demand shift outlasts the prescription, which means category economics are being reset rather than dented.

Knowing where your category sits on this map will be critical to how you plan, innovate and compete. Our full report explores this across six categories. 

Appetite for disruption:

What GLP-1 means for consumer markets

(PDF of 6.81MB)

Category spotlights

Coming soon

Over the coming weeks, we'll be releasing deeper category insights including the following.

- Vitamins
- Apparel
- Fitness
- Restaurants

Contact us

Jacqueline Windsor

Jacqueline Windsor

UK Head of Retail and Strategy& Partner, PwC United Kingdom

Tel: +44 (0)7801 074739

Inge Cajot

Inge Cajot

Strategy& Deals Partner, PwC United Kingdom

Tel: +44 (0)7764 235425

Sam Waller

Sam Waller

Leader of Industry for Consumer Markets, PwC United Kingdom

Tel: +44 (0)7850 515966

Emma Burton

Emma Burton

Strategy& Consumer Markets Director, PwC United Kingdom

Tel: +44 (0)7483 407151

Follow us